Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans mtcc 5856
- Development stage
- Preclinical
- Lead developer
- Sabinsa
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans MTCC 5856 is a specific, patented strain of spore-forming probiotic bacteria developed and manufactured by Sabinsa Corporation and marketed under the brand name LactoSpore®. [1, 2, 7] As a spore-forming organism, it is highly stable at room temperature and can survive the acidic environment of the stomach to germinate and proliferate in the intestines. [7, 13] It has received Generally Recognized as Safe (GRAS) status from the US FDA. [4, 14] Clinical studies have evaluated its efficacy in managing digestive health issues. Notably, a pilot clinical study demonstrated that supplementation with B. coagulans MTCC 5856 improved symptoms of both major depressive disorder (MDD) and irritable bowel syndrome (IBS) in patients with both conditions. [4, 6, 8] The proposed mechanism involves modulating the gut microbiome and the gut-brain axis, which was supported by a significant reduction in the inflammatory biomarker myeloperoxidase in study participants. [4] Other studies have also shown its effectiveness in improving symptoms of diarrhea-predominant IBS and functional gas and bloating. [3, 4, 11]
- Brand names
- LactoSpore
- Other names
- Weizmannia coagulans MTCC 5856
Beyond the preview
Go deeper on bacillus coagulans mtcc 5856.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans mtcc 5856.